RxDoctor Payments Data

Shauni Williams, NP

Nurse Practitioner · Redding, CANPI 1952957474

Payments from drug & device makers

$635in general payments, 2019–2025

Across 20 payments — averaging $31.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$206
  • AstraZeneca$135
  • Lilly USA, LLC$65
  • AbbVie$43
  • Bayer$28
  • Eisai Inc.$24
  • plus $134 from 7 others

What the payments were for

  • Food & beverage$45071%
  • Education$18529%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$635 in reported general payments places this provider in the 70th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$173,696
Medicare patients
432
Services billed
2,435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$55,699
JardianceEmpagliflozin32$41,061
EliquisApixaban30$30,422
MounjaroTirzepatide22$25,842
KerendiaFinerenone18$20,988
XareltoRivaroxaban15$19,106
MyrbetriqMirabegron25$15,626
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,696
LinzessLinaclotide12$9,163
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$7,693
Topiramate19$2,611
Levothyroxine Sodium257$2,610
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen124$2,387
Losartan Potassium313$2,286
Potassium Chloride100$2,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$21$55,69952 claims
PfizerEliquis$21$30,42230 claims
Lilly USA, LLCMounjaro$65$25,84222 claims
BayerKerendia$28$20,98818 claims
Astellas Pharma US IncMyrbetriq$206$15,62625 claims
AbbVieLinzess, Synthroid$43$10,32744 claims
AstraZenecaBreztri Aerosphere$135$7,69313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →